Autologous T Cells Expressing a High Affinity TCR Specific for NY-ESO-1 (LauT-1) therapy(Centre Hospitalier Universitaire Vaudois)

N/A

Report date: 2025/03/26 20:01:25

Base Information

Drug NameAutologous T Cells Expressing a High Affinity TCR Specific for NY-ESO-1 (LauT-1) therapy(Centre Hospitalier Universitaire Vaudois)
Drug Alias NameLauT-1
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionAnti-NY-ESO-1T lymphocyte replacements
TargetsCancer/testis antigen 1
Therapy Area/IndicationsMelanomaSarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCentre Hospitalier Universitaire Vaudois
China Registration ClassN/A

Develop Information

Active CompaniesCentre Hospitalier Universitaire Vaudois
Inactive CompaniesN/A
Active IndicationsMelanomaSarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A